KALA BIO, INC. Revenue from Contract with Customer, Including Assessed Tax
KALA BIO, INC. (KALA) reported Revenue from Contract with Customer, Including Assessed Tax of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-04-15
- KALA BIO, INC. revenue from contract with customer, including assessed tax for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- KALA BIO, INC. revenue from contract with customer, including assessed tax for the quarter ending 2022-09-30 was $420.00K, a 86.31% decline year-over-year.
- KALA BIO, INC. revenue from contract with customer, including assessed tax for the quarter ending 2022-06-30 was $2.10M, a 31.17% decline year-over-year.
- KALA BIO, INC. revenue from contract with customer, including assessed tax for the quarter ending 2022-03-31 was $1.37M, a 57.99% decline year-over-year.
- KALA BIO, INC. revenue from contract with customer, including assessed tax for fiscal 2025 was $0.00.
- KALA BIO, INC. revenue from contract with customer, including assessed tax for fiscal 2024 was $0.00.
- KALA BIO, INC. revenue from contract with customer, including assessed tax for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- KALA BIO, INC. revenue from contract with customer, including assessed tax for fiscal 2022 was $3.89M, a 65.37% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-04-15 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-04-15 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-31 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $420.00K derived: sum of 2 quarters · filed 2024-03-29 | $2.52M derived: sum of 3 quarters · filed 2024-03-29 | $3.89M 10-K · filed 2024-03-29 |
| 2022-09-30 | $420.00K 10-Q · filed 2023-11-13 | $2.52M derived: sum of 2 quarters · filed 2023-11-13 | $3.89M 10-Q · filed 2023-11-13 | $5.75M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $2.10M 10-Q · filed 2023-08-04 | $3.47M 10-Q · filed 2023-08-04 | $5.33M derived: sum of 3 quarters · filed 2023-08-04 | $8.39M derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | $1.37M 10-Q · filed 2023-05-09 | $3.23M derived: sum of 2 quarters · filed 2023-05-09 | $6.29M derived: sum of 3 quarters · filed 2023-05-09 | $9.35M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $1.86M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $4.92M derived: sum of 2 quarters · filed 2023-03-03 | $7.97M derived: sum of 3 quarters · filed 2023-03-03 | $11.24M 10-K · filed 2023-03-03 |
| 2021-09-30 | $3.07M 10-Q · filed 2022-11-08 | $6.12M derived: sum of 2 quarters · filed 2022-11-08 | $9.38M 10-Q · filed 2022-11-08 | $11.62M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $3.05M 10-Q · filed 2022-08-11 | $6.32M 10-Q · filed 2022-08-11 | $8.55M derived: sum of 3 quarters · filed 2022-08-11 | $10.78M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $3.27M 10-Q · filed 2022-05-16 | $5.50M derived: sum of 2 quarters · filed 2022-05-16 | $7.72M derived: sum of 3 quarters · filed 2022-05-16 | $8.56M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $2.24M 10-K · filed 2021-02-25 | $4.46M derived: sum of 2 quarters · filed 2021-11-15 | $5.29M derived: sum of 3 quarters · filed 2021-11-15 | $6.36M 10-K · filed 2022-03-29 |
| 2020-09-30 | $2.22M 10-Q · filed 2021-11-15 | $3.05M derived: sum of 2 quarters · filed 2021-11-15 | $4.12M 10-Q · filed 2021-11-15 | $5.30M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $833.00K 10-Q · filed 2021-08-05 | $1.90M 10-Q · filed 2021-08-05 | $3.08M derived: sum of 3 quarters · filed 2021-08-05 | $4.54M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $1.07M 10-Q · filed 2021-05-05 | $2.25M derived: sum of 2 quarters · filed 2021-05-05 | $3.70M derived: sum of 3 quarters · filed 2021-05-05 | $5.76M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | $1.18M 10-K · filed 2021-02-25 | $2.63M derived: sum of 2 quarters · filed 2021-02-25 | $4.69M derived: sum of 3 quarters · filed 2021-02-25 | $6.07M 10-K · filed 2021-02-25 |
| 2019-09-30 | $1.45M 10-K · filed 2021-02-25 | $3.51M derived: sum of 2 quarters · filed 2021-02-25 | $4.89M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $2.06M 10-K · filed 2021-02-25 | $3.44M 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $1.39M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |